Iterum Therapeutics (NASDAQ:ITRM) Rating Increased to Buy at ValuEngine

Share on StockTwits

ValuEngine upgraded shares of Iterum Therapeutics (NASDAQ:ITRM) from a hold rating to a buy rating in a report published on Wednesday morning, ValuEngine reports.

Several other brokerages also recently commented on ITRM. Zacks Investment Research upgraded Iterum Therapeutics from a sell rating to a hold rating in a report on Wednesday, July 17th. HC Wainwright reiterated a buy rating and set a $17.00 price target on shares of Iterum Therapeutics in a report on Thursday, August 15th. Finally, Royal Bank of Canada lowered their price target on Iterum Therapeutics to $17.00 and set an outperform rating on the stock in a report on Wednesday, May 15th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. Iterum Therapeutics has a consensus rating of Buy and an average target price of $15.75.

Shares of ITRM stock opened at $6.41 on Wednesday. Iterum Therapeutics has a 12 month low of $4.70 and a 12 month high of $11.22. The company has a current ratio of 2.10, a quick ratio of 2.10 and a debt-to-equity ratio of 0.44. The business’s 50 day moving average is $6.65 and its two-hundred day moving average is $6.85.

Iterum Therapeutics (NASDAQ:ITRM) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($1.93) EPS for the quarter, missing the consensus estimate of ($1.50) by ($0.43). Iterum Therapeutics had a negative net margin of 11,956.64% and a negative return on equity of 136.21%. As a group, research analysts forecast that Iterum Therapeutics will post -6.74 EPS for the current year.

About Iterum Therapeutics

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.

See Also: Why Dividend Stocks May Be Right for You

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.